Status:
COMPLETED
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
Lead Sponsor:
Janssen-Ortho LLC
Collaborating Sponsors:
Ortho-McNeil Neurologics, Inc.
Conditions:
Migraine
Eligibility:
All Genders
12-17 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents. Amotriptan malate (AXERT®) is approved for use...
Detailed Description
Amotriptan malate (AXERT®) is approved for use in the treatment of acute migraine headache with or without aura in adults. Other studies have shown that almotriptan is effective and well tolerated in ...
Eligibility Criteria
Inclusion
- Diagnosis of migraine with or without aura for \> 1 year
- Average of 1 to 6 moderate or severe migraines per month for 2 months before entering the study
- Untreated migraines lasting at least 4 hours
- At least 24 hours between migraines
- Able to tell the difference between migraines and other types of headache
- If female, using birth control
Exclusion
- Chronic tension or cluster headache
- Prolonged aura
- Specific types of migraine
- \> 6 nonmigraine headaches per month
- High blood pressure for the age
- Medical history with specific significant conditions affecting the liver, kidney, heart or other body systems
- Conditions that might affect the way the body absorbs or processes a drug
- Positive blood tests for Hepatitis B or C
- Recent head or neck injury
- Body weight outside given parameters
- Unable to take sumatriptan
- Abusing drugs or alcohol
- Pregnant or breast-feeding
- Use of antimigraine medication that might interfere with the study, of antimigraine medication for \< 2 weeks, of lithium or monoamine oxidase inhibitors in past 2 weeks, of an investigational drug within 2 months
- Refuse to abstain from taking medicine with ergotamine or any other drug like almotriptan within 48 hours before and 24 hours after taking study medication, or drugs containing opiates or antivomiting medicine within 48 hours before and 2 hours after taking study medication
- Use of simple pain medicines within 24 hours (like aspirin)
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
866 Patients enrolled
Trial Details
Trial ID
NCT00210483
Start Date
July 1 2003
End Date
July 1 2005
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.